MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)

Mirum and Incyte’s zilurgisertib reduced new bone lesion formation in rare disease FOP, while the FDA also began Priority Review of the NDA. The agency set a decision date of Sept. 26, 2026, which is a meaningful regulatory milestone for the program. The update is supportive for both companies, though the market impact is likely limited to the individual stocks rather than the broader sector.

Analysis

Mirum and Incyte’s zilurgisertib reduced new bone lesion formation in rare disease FOP, while the FDA also began Priority Review of the NDA. The agency set a decision date of Sept. 26, 2026, which is a meaningful regulatory milestone for the program. The update is supportive for both companies, though the market impact is likely limited to the individual stocks rather than the broader sector.